NASHVILLE, Tenn.--(BUSINESS WIRE)--VION Biosciences, a life science platform company focused on specialty materials in the life science research, diagnostics, and drug discovery spaces, announced its January 2025 acquisition of San Francisco area-based BioAssay Systems, a biotech company that develops and offers innovative high-throughput assay solutions for life sciences and drug discovery. This acquisition serves as the fourth investment under the VION platform, continuing its growth in developing proprietary products for life science research.
CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--VION Biosciences, a life science platform company focused on specialty materials in the life science research, diagnostics, and drug discovery spaces, today announced Vince Stoyanov as its Chief Strategy and Development Officer. He will lead corporate development, mergers and acquisitions (M&A), and other related corporate functions, bringing both expertise and continued energy to VION at a critical moment in its expansion efforts.
Duis aute irure dolor in reprehenderit
in voluptate velit esse cillum dolore eufugiat nulla pariatur. Excepteur sint occaecat cupidatat non proidentsunt.
CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--VION Biosciences, a life science platform company focused on specialty reagents in the life science research, diagnostic, and drug discovery space, announced the recent acquisition of Salt Lake City-based Echelon Biosciences, a trusted supplier of critical materials, notably lipid-based excipients, to its growing portfolio. This acquisition serves as the second investment under VION Biosciences LLC (“VION Biosciences”), Iron Path Capital’s roll-up platform in the life science sector led by life science industry veteran, Mark Thornton.
VION Biosciences
Empowering a World of Discovery
Partner with Vion Biosciences to drive innovation in life sciences and beyond. Let us provide the solutions to power your success.
